




State of Louisiana
Louisiana Department of Health
Bureau of Health Services Financing

To: Rebekah E. Gee, MD, MPH
Secretary LDH

From: Jen Steele 
Medicaid Director


Date: November 20, 2019

Re: Recommendation to Change the Status of Enbrel on the Medicaid
Preferred Drug List (PDL) until Reviewed by the P&T Committee

LDH Medicaid Pharmacy staff reviewed the clinical efficacy and potential financial impact of the Cytokine and CAM Antagonists therapeutic class and recommends changing the prior authorization status of Enbrel from non-preferred to preferred until review by the Pharmaceutical and Therapeutics (P&T) Committee. It is anticipated if Enbrel is switched from non-preferred to preferred the drug would be more accessible to Medicaid recipients at a lower cost to the State. The effective date will be January 1, 2020.

Etanercept (**Enbrel®**) was reviewed and recommended by LDH Pharmacy staff for the **PDL until review by the P&T Committee.**

Approve LDH staff's Recommendation

 Candy Rivers

Disapprove LDH staff's Recommendation